

~ Sickle Cell Disease Therapy ~

Prior Authorization Request Form

In order for members to receive Medicaid coverage for medications that require prior authorization, the prescriber must complete and fax this form to Change Healthcare. Please complete this form in its entirety and sign and date below. Incomplete requests will be returned for additional information. For questions, please contact the Change Healthcare helpdesk at 1-844-679-5363.

Submit request via Fax: 1-844-679-5366

| Prescr | ibing provider: | Member: | | | |
|---------------------------|--|---|--|---|-------------------------------------|
| | : | Name: | | | |
| Physic | ian NPI: | Medicaid ID#: | | Cove | • |
| Specia | lty: | Date of Birth: | | Sex: | |
| Phone | #: | Patient's Phone: | | | |
| Fax#: | | Pharmacy Name | | | |
| Addre | SS: | Pharmacy NPI: | | | |
| Contac | ct Person at Office: | Pharmacy Phone: | | Pharmacy Fax: | |
| he foll | lowing MUST be completed for MEDICAL I | BENEFIT requests: | | | |
| НС | CPCS J-code(s): | , CPT code(s): | | | |
| Ac | dministering Provider/Facility: Name | N | IPI# | Medicaid ID# | |
| Co | ontact person at facility: | Phone # | F | ax number: | |
| Wi | ill this require an inpatient stay? Yes \Box N | o 🗆 | | | |
| | If yes: Date of admission (if known | vn) Da ⁻ | te of procedure | e (if known) | _ |
| | Expected length of inpatient stay | | | | |
| | Out-of-network office visits and admissions | | on: | | |
| <u> </u> | Health Access Gene Therapy Authorization https://dvha.vermont.gov/forms-manuals/ | Guide for more informati forms/clinical-prior-autho | orization-forms | | |
| H <u>H</u> Dr | Health Access Gene Therapy Authorization https://dvha.vermont.gov/forms-manuals/ ug Requested: | Guide for more informati forms/clinical-prior-autho | orization-forms | | |
| H <u>t</u> Dr Pa | Health Access Gene Therapy Authorization https://dvha.vermont.gov/forms-manuals/ug Requested: Strengt | Guide for more informati forms/clinical-prior-autho th/Route/Frequency: | orization-forms | | - do-o-) |
| H <u>t</u> Dr Pa | Health Access Gene Therapy Authorization https://dvha.vermont.gov/forms-manuals/ ug Requested: | Guide for more informati forms/clinical-prior-autho th/Route/Frequency: | orization-forms | | e dose) |
| Pa (A | Health Access Gene Therapy Authorization https://dvha.vermont.gov/forms-manuals/ug Requested: Strengt | Guide for more informati forms/clinical-prior-authon th/Route/Frequency: totemcel) or Lyfgenia™ (lo | ovotibeglogene or other record | autotemcel) will be for a single | uest): |
| Pa (A | Health Access Gene Therapy Authorization nttps://dvha.vermont.gov/forms-manuals/ ug Requested: Strengt pproval for Casgevy TM (exagamglogene authorization) Please provide details of prior hydroxyur | Guide for more informati forms/clinical-prior-authon th/Route/Frequency: totemcel) or Lyfgenia TM (In rea therapy (clinical notes | ovotibeglogene or other record | ds should be included with requ | uest): |
| Dr Pa (A | Health Access Gene Therapy Authorization https://dvha.vermont.gov/forms-manuals/ ug Requested: tient Weight (kg): pproval for Casgevy TM (exagamglogene authorized provide details of prior hydroxyum Dates of Trial: | Guide for more informati forms/clinical-prior-author th/Route/Frequency: totemcel) or Lyfgenia TM (lor rea therapy (clinical notes | ovotibeglogene or other record | ds should be included with requ | uest): |
| Dr Pa (A | Health Access Gene Therapy Authorization https://dvha.vermont.gov/forms-manuals/ ug Requested: Strengt pproval for Casgevy TM (exagamglogene authorization proval for Casgevy prior hydroxyum Dates of Trial: Reason for Failure: Has the patient experienced 2 or more visual prior hydroxyum pates of Trial: Reason for Failure: Has the patient experienced 2 or more visual prior hydroxyum pates of Trial: Reason for Failure: Has the patient experienced 2 or more visual prior hydroxyum pates of Trial: Reason for Failure: Has the patient experienced 2 or more visual prior hydroxyum pates of Trial: Reason for Failure: Has the patient experienced 2 or more visual prior hydroxyum pates of Trial: Reason for Failure: Has the patient experienced 2 or more visual prior hydroxyum pates of Trial: Reason for Failure: Reason for Reason for Reason for Reason for Reason for Reason for | Guide for more information of the forms/clinical-prior-authors of the forms/clinical-prior-authors of the forms/clinical-prior-authors of the forms/clinical notes of the forms/clinical-prior-authors/clinical-prior-autho | ovotibeglogene or other record | ds should be included with requests despite compliance with hyd | uest): roxyurea ² |
| Dr Pa (A | Health Access Gene Therapy Authorization https://dvha.vermont.gov/forms-manuals/ ug Requested: Strengt tient Weight (kg): Strengt pproval for Casgevy TM (exagamglogene authorization Prior hydroxyur Dates of Trial: Reason for Failure: Has the patient experienced 2 or more value (Documentation Provided) | Guide for more information forms/clinical-prior-authors th/Route/Frequency: totemcel) or Lyfgenia™ (Increa therapy (clinical notes) aso-occlusive crises in the quire documentation show | ovotibeglogene or other record | autotemcel) will be for a singleds should be included with requal Dose: as despite compliance with hyder in the frequency or severity o | uest): roxyurea |
| Dr Pa (A 1. | Health Access Gene Therapy Authorization https://dvha.vermont.gov/forms-manuals/ ug Requested: tient Weight (kg): pproval for Casgevy TM (exagamglogene authorization Prior hydroxyur Dates of Trial: Reason for Failure: Has the patient experienced 2 or more var (Documentation Provided) Yes No (Renewal Requests will reconstructed Please provide baseline Hemoglobin and | Guide for more information forms/clinical-prior-authors th/Route/Frequency: totemcel) or Lyfgenia™ (Increa therapy (clinical notes) aso-occlusive crises in the quire documentation show | ovotibeglogene or other record past 12 month wing a decrease ry test(s) or pro | autotemcel) will be for a singleds should be included with requal Dose: as despite compliance with hyder in the frequency or severity o | uest): roxyurea |
| Dr Pa (A 1. | Health Access Gene Therapy Authorization https://dvha.vermont.gov/forms-manuals/ ug Requested: tient Weight (kg): pproval for Casgevy TM (exagamglogene authorization Prior hydroxyur Dates of Trial: Reason for Failure: Has the patient experienced 2 or more var (Documentation Provided) Yes No (Renewal Requests will reconstructed Please provide baseline Hemoglobin and | Guide for more information forms/clinical-prior-authors th/Route/Frequency: totemcel) or Lyfgenia TM (lorea therapy (clinical notes) aso-occlusive crises in the quire documentation show other pertinent laborators | ovotibeglogene or other record past 12 month wing a decrease ry test(s) or pro | ds should be included with requests despite compliance with hyde in the frequency or severity oncedure(s) if applicable: | uest): roxyurea |
| Dr Pa (A 1. | Health Access Gene Therapy Authorization https://dvha.vermont.gov/forms-manuals/ ug Requested: tient Weight (kg): Strengt pproval for Casgevy TM (exagamglogene aut Please provide details of prior hydroxyur Dates of Trial: Reason for Failure: Has the patient experienced 2 or more var (Documentation Provided) Yes □ No □ (Renewal Requests will reconstructed provide baseline Hemoglobin and Procedure | Guide for more information forms/clinical-prior-authors th/Route/Frequency: totemcel) or Lyfgenia TM (lorea therapy (clinical notes) aso-occlusive crises in the quire documentation show other pertinent laborators | ovotibeglogene or other record past 12 month wing a decrease ry test(s) or pro | ds should be included with requests despite compliance with hyde in the frequency or severity of cedure(s) if applicable: | uest): roxyurea |
| Dr Pa (A 1. 2. 3. | Health Access Gene Therapy Authorization https://dvha.vermont.gov/forms-manuals/ ug Requested: tient Weight (kg): Strengt pproval for Casgevy TM (exagamglogene aut Please provide details of prior hydroxyur Dates of Trial: Reason for Failure: Has the patient experienced 2 or more var (Documentation Provided) Yes □ No □ (Renewal Requests will reconstructed provide baseline Hemoglobin and Procedure | Guide for more information of the forms/clinical-prior-authors of the forms/clinical-prior-authors of the forms/clinical notes of the forms of the | ovotibeglogene or other record past 12 month wing a decrease ry test(s) or pro | autotemcel) will be for a single ds should be included with requess despite compliance with hyde in the frequency or severity of cedure(s) if applicable: | roxyurea |

Date: _____

requested in the prior authorization request may subject me to audit and/or recoupment.

Prescribers Signature:

Last Updated 07/2024